Document:

Agreement to Amend Research and License Agreement

 EXHIBIT 10.29 
  
 Agreement to Amend 
 Research and License Agreement 
  
 This Agreement,
dated as of April 23, 2002, is by and between OXiGENE, Inc. 321 Arsenal Street, Watertown, Massachusetts 02472 (“OXiGENE”) and Baylor University, Waco, Texas 76798 (the “University”). OXiGENE and the University may be referred to
collectively as the “Parties” or individually as a “Party.” 
  
 WHEREAS, Parties entered into a certain Research and License Agreement, dated June 1, 1999; 
  
 WHEREAS, the Parties desire to amend and clarify the Research and License Agreement pursuant to Section 15.2 of such agreement; 
  
 NOW THEREFORE for valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, and intending to be legally bound, the Parties mutually agree as follows: 
  
 1. Any defined terms that are not defined in this Agreement shall have the meaning given in the Research and License Agreement. 
  
 2. Section 1.5 of the Research and License shall be deleted and replaced with
the following language: 
  
 “Existing Patent
Rights” shall mean all Patent Rights deriving from US Patent No. 5,886,025, filed on March 6, 1997 and issued on March 23, 1999, and from International Application No. PCT/US9S/04380, filed on March 6, 1998. Applications stemming from this
PCT application are accorded the PCT filing date of March 8, 1998. 
  
 3. Appendix B, which is attached hereto, is amended and restated to include all Biological Materials, Joint Intellectual Property and University Research Property 

 
from the Effective Date of the Research and License Agreement until the date of this Agreement. If any Party later determines that any Biological Materials,
Joint Intellectual Property or University Research Property arising out of the Research Program or any Inventions made under the Superseded Agreement were omitted from Appendix B, such Party shall immediately provide written notice to the other
Party of such omission and Appendix B shall be amended accordingly. 
  
 4. Within ninety (90) days of the date that this Agreement is signed, the University shall provide to OXiGENE a complete list of all Biological Materials identified or synthesized by the University since the Effective Date. 
  
 5. Appendix C, which is attached hereto, is amended and restated to include
all elected Inventions included therein. 
  
 6. All patent
prosecution and maintenance expenses incurred in connection with University Intellectual Property and billed to the University since the Effective Date of the Research and License Agreement shall be itemized and invoiced to OXiGENE within sixty (60)
days of the date of this Agreement. The Parties agree that OXiGENE will make quarterly payments to reimburse the University in full for such expenses over the course of the next four (4) calendar quarters commencing July 1, 2002. 
  
 7. The University or its patent counsel shall invoice OXiGENE for all future
patent prosecution and maintenance payments on University Intellectual Property on a monthly basis. 
  
 8. All provisions of the Research and License Agreement not amended by this Agreement shall remain in full force and effect. 

 IN WITNESS WHEREOF, and intending to be bound hereby, each Party has caused this Agreement to be signed
by its duly authorized representative. 
  

	OXiGENE, INC.
		
	 By:
	 	 /s/    FREDERICK W. DRISCOLL 

	 	 	 Name: Frederick W. Driscoll
 Title:
President & CEO
 Date: May 13, 2002

  
  

	BAYLOR UNIVERSITY
		
	 By:
	 	 /s/    DONALD D. SCHMELTEKOPF 

	 	 	 Name: Donald D. Schmeltekopf
 Title:
Provost and Vice President
 for Academic Affairs
 Date: May 10, 2002

  

		
	 Attest:
	 	 /s/    MARSHA J. DUCKWORTH 

	 	 	 

  

 APPENDIX B 
  
 BIOLOGICAL MATERIALS, JOINT INTELLECTUAL PROPERTY, 
 UNIVERSITY INTELLECTUAL PROPERTY AND PATENT RIGHTS 
  
 Biological Materials include all Biological Material identified since the Effective Date of the Research and License Agreement regardless of whether or not proper
notice was provided pursuant to Section 3.1 of the Research and License Agreement. 
  
 Existing Patent Rights include: 
  

	1)	 	US Patent No. 5,886,025, issued on March 23, 1999 and granted to Kevin Pinney, entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	2)	 	US Patent No. 6,162,930, issued on December 19, 2000 and granted to Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	3)	 	US Patent No. 6,350,777, issued on February 26, 2002 and granted to Kevin Pinney et al., entitled “Description Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	4)	 	Australian Patent No. 732,917, issued on August 16, 2001 and granted to Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	5)	 	Australian Divisional Patent Application No. 24860/01, filed on March 6, 1998 by Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	6)	 	Canadian Patent Application No. 2,283,471, filed on March 6, 1998 by Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	7)	 	European Patent Application No. 98908991.7, filed on March 6, 1998 by Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  

	8)	 	Japanese Patent Application No. 10-538834, filed on March 6, 1998 by Kevin Pinney et al., entitled “Anti-mitotic Agents which Inhibit Tubulin Polymerization.”

  
 Joint Intellectual Property include all inventions
described and/or claimed in the following patent applications and any patents issuing from said applications, including 

 
any foreign filings, divisions, continuations, continuations-in-part, reexaminations, extensions, or reissues: 
  

	1)	 	US Provisional Patent Application No. 60/337,348, filed on October 26, 2001 by David Chaplin et al., entitled “Functionalized Z and E Stilbene Derivatives as Improved Vascular
Targeting Agents.” 

  
 University Intellectual Property
includes all inventions described and/or claimed in the Existing Patent Rights, as well as the following US or PCT applications and any patents issuing from said applications, including any foreign filings, divisions, continuations,
continuations-in-part, reexaminations, extensions, or reissues: 
  

	1)	 	International Application No. PCT/US00/25408, filed on September 15, 2000 and published with WIPO Publication No. WO 01/19794, entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	2)	 	Australian Application No. 74934/00, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	3)	 	Canadian Patent Application (Application No. has not been assigned), filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	4)	 	Japanese Application No. 523374/01, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	5)	 	European Application No. 00963531.9, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	6)	 	US Patent Application No. 10/070,484, filed March 6, 2002, entitled “Indole-containing and Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents.”

  

	7)	 	International Application No. PCT/US01/07539, filed on March 9, 2001 and published with WIPO Publication No. WO 01/68654, entitled “Tubulin Binding Ligands and Corresponding
Prodrug Constructs.” 

  

	8)	 	US Patent Application No. 09/804,280 filed March 12,2001, entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs”. 

 APPENDIX C 
  
 ELECTED INVENTIONS 
  
 Non-Exclusive Licenses: 
  
 Exclusive Licenses: 
  

	1)	 	International Application No. PCT/US00/25408, filed on September 15, 2000 and published with WIPO Publication No. WO 01/19794, entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	2)	 	Australian Application No. 74934/00, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents” 

  

	3)	 	Canadian Patent Application (Application No. has not been assigned), filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	4)	 	Japanese Application No. 523374/01, flied on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	5)	 	European Application No. 00963531.9, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	6)	 	US Patent Application No. 10/070,484, filed March 6, 2002, entitled “Indole-containing and Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents.”

  

	7)	 	International Application No. PCT/US01/07539, filed on March 9, 2001 and published with WIPO Publication No. WO 01/68654, entitled “Tubulin Binding Ligands and Corresponding
Prodrug Constructs.” 

  

	8)	 	US Patent Application No. 09/804,280, entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.” 

  

	9)	 	US Provisional Patent Application No. 60/337,348, filed on October 26, 2001 by David Chaplin et al., entitled “Functionalized Z and E Stilbene Derivatives as Improved Vascular
Targeting Agents.”"Addendum"  to Research and License Agreement

 EXHIBIT 10.30 
  
 “ADDENDUM” 
  
 With the understanding that all material aspects of both the June 1, 1999, Research and License Agreement and the April 23, 2002, Agreement to Amend Research and License
Agreement remain in full force and effect, the parties hereby agree to amend and restate Appendix C, which is attached hereto, to include all elected Inventions included therein, pursuant to Section 4.2 of the June 1, 1999, Research and License
Agreement. 
  
 IN WITNESS WHEREOF, and intending to be bound hereby, each Party
has caused this Agreement to be signed. 
  

	OXiGENE, INC.
		
	 By:
	 	 /s/    FREDERICK W. DRISCOLL 

	 	 	 Name: Frederick W. Driscoll
 Title:
President & CEO

  

	BAYLOR UNIVERSITY
		
	 By:
	 	 /s/    DONALD D. SCHMELTEKOPF

	 	 	 Name: Donald D. Schmeltekopf
 Title:
Provost & VP for Academic Affairs

  

	ATTEST:
		
	 By:
	 	 /s/    MARSHA J. DUCKWORTH 

	 	 	 

 APPENDIX C 
  
 ELECTED INVENTIONS 
  
 Non-Exclusive Licenses: 
  
 Exclusive Licenses: 
  

	1)	 	International Application No. PCT/US00/25408, filed on September 15, 2000 and published with WIPO Publication No. WO 01/19794, entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	2)	 	Australian Application No. 74934/00, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	3)	 	Canadian Patent Application (Application No. has not been assigned), filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and
Combretastatin-related Anti-mitotic and Anti-tubulin Polymerization Agents”. 

  

	4)	 	Japanese Application No. 523374/01, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents.” 

  

	5)	 	European Application No. 00963531.9, filed on September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitotic and
Anti-tubulin Polymerization Agents”. 

  

	6)	 	US Patent Application No. 10/070,484, filed September 15, 2000 claiming priority to PCT/US00/25408 entitled “Indole-containing and Combretastatin-related Anti-mitrotic and
Anti-tubulin Polymerization Agents.” 

  

	7)	 	International Application No. PCT/USO1/07539, filed on March 9, 2001 and published with WIPO Publication No. WO 01/68654, entitled “Tubulin Binding Ligands and Corresponding
Prodrug Constructs.” 

  

	8)	 	Australian Application No. 2001243527, claiming priority to PCT/US01/07539 filed on March 9, 2001 entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.”

  

	9)	 	Canadian Application No. 2,407,967, claiming priority to PCT/USO1/07539 filed on March 9, 2001 entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.”

  

	10)	 	European Application No. 01916509.1, claiming priority to PCT/US01/07539 filed on March 9, 2001 entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.”

  

	11)	 	Japanese Application No. 2001-567745, claiming priority to PCT/USO1/07539 filed on March 9, 2001 entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.”

  

	12)	 	US Patent Application No. 09/804,280, March 12, 2001 entitled “Tubulin Binding Ligands and Corresponding Prodrug Constructs.” 

  

	13)	 	US Patent Application No. 10/281,528, filed on October 28, 2002 by David Chaplin et al., entitled “Functionalized Stilbene Derivatives as Improved Vascular Targeting
Agents.” 

  

	14)	 	US Provisional Patent Application No. 60/430,397, filed on December 3, 2002 by Robert Kane et al., entitled “Nucleoside Prodrugs Resistant to Metabolic Deactivation.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]